COVERSYL - COVERSYL - CT 4792 - English version

Has

Description

Introduction COVERSYL 2 mg tablets Box of 30 (CIP: 331032-7) Box of 90 (CIP: 331035-6) Box of 100 (CIP: 558521-2) COVERSYL 4 mg scored tablets Box of 30 (CIP 331024-4); Box of 90 (CIP 331026-7); Box of 100 (CIP 558334-8) COVERSYL 8 mg tablets Box of 30 (CIP 362503-1); Box of 90 (CIP 362505-4); Box of 100 (CIP 362506-0) Posted on Apr 20 2009 Active substance (DCI) perindopril ATC Code C09AA04 Laboratory / Manufacturer SERVIER COVERSYL 2 mg tablets Box of 30 (CIP: 331032-7) Box of 90 (CIP: 331035-6) Box of 100 (CIP: 558521-2) COVERSYL 4 mg scored tablets Box of 30 (CIP 331024-4); Box of 90 (CIP 331026-7); Box of 100 (CIP 558334-8) COVERSYL 8 mg tablets Box of 30 (CIP 362503-1); Box of 90 (CIP 362505-4); Box of 100 (CIP 362506-0) Posted on Apr 20 2009

Sujets

• Médecine

Informations

• Publié par: haute-autorite-sante-traitement-medicamenteux
• Publié le: 23 janvier 2008
• Nombre de lectures: 17
• Licence : En savoir +
  Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
• Langue: English

Extrait

   

 

  The legally binding text is the original French version   TRANSPARENCY COMMITTEE

Opinion   23 January 2008     COVERSYL 2 mg tablets Box of 30 (CIP: 331032-7) Box of 90 (CIP: 331035-6) Box of 100 (CIP: 558521-2)   COVERSYL 4 mg scored tablets Box of 30 (CIP 331024-4); Box of 90 (CIP 331026-7); Box of 100 (CIP 558334-8)   COVERSYL 8 mg tablets Box of 30 (CIP 362503-1); Box of 90 (CIP 362505-4); Box of 100 (CIP 362506-0)   Applicant SERVIER   perindopril    List I   Date of initial marketing authorisations: COVERSYL 2 and 4 mg tablets: 22 June 1988 COVERSYL 8 mg: 16 December 2003   Extension of indication to “stable coronary artery disease”: COVERSYL 2 and 4 mg: 3 February 2006 (mutual recognition) COVERSYL 8 mg: 6 September 2006 (national procedure):   Reason for request: Inclusion on the list of medicines reimbursed by National Insurance (B/30 and B/90) and approved for hospital use (B/30, B/90 and B/100) for the new indication: “Stable coronary artery disease: Reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation”.                             Health Technology Assessment Division

 

1